Hong Kong Electric Utilities Stock News

What China XLX Fertiliser’s latest earnings mean for investors China XLX Fertiliser (SEHK:1866) just released its 2025 annual results, pairing modest profit growth after non recurring items with a 23.1% dividend increase, an improved borrowing mix, and ongoing expansion of new production bases. See our latest analysis for China XLX Fertiliser. The earnings release has arrived alongside a sharp 9.5% 1 day share price return, adding to a 90 day share price return of 28.2% and a very large 1...

PetroChina (SEHK:857) has laid out a steady set of FY 2025 numbers, with fourth quarter revenue at C¥695.2b and basic EPS of C¥0.17, while trailing twelve month revenue stands at C¥2.86t and EPS at C¥0.86. Over recent periods the company has seen quarterly revenue move between C¥681.7b and C¥753.1b and basic EPS range from C¥0.17 to C¥0.26. This gives you a clear view of how the top line and per share earnings have tracked into the latest print. With a trailing net profit margin near the mid...

Zhongyu Energy Holdings (SEHK:3633) opened FY 2025 with first half revenue of about HK$6.6b and basic EPS of HK$0.089, setting a cleaner profit picture against a share price of HK$2.68. The company reported revenue of roughly HK$7.3b in 1H 2024 and HK$6.6b in 1H 2025, while basic EPS moved from HK$0.086 in 1H 2024 to HK$0.089 in the latest period. This leaves investors with a results set where modest EPS progress sits alongside a relatively slim earnings margin profile. See our full analysis...

Goodbaby International Holdings (SEHK:1086) FY 2025 earnings snapshot Goodbaby International Holdings (SEHK:1086) has released its FY 2025 numbers with first half revenue of HK$4.3b and basic EPS of HK$0.06. This provides context for how you might weigh the latest results against the share price of HK$0.99. Over recent periods, the company has reported revenue between HK$4.2b and HK$4.6b per half, while basic EPS ranged from HK$0.11 to HK$0.06, giving a clear view of how the top line and per...

Xinte Energy (SEHK:1799) has reported FY 2025 first half revenue of C¥7.3b with a basic EPS loss of C¥0.18, while trailing twelve month revenue sits at C¥15.3b against a basic EPS loss of C¥0.84. Over recent periods, the company has seen revenue move from C¥11.7b in 1H 2024 to C¥9.5b in 2H 2024 before landing at C¥7.3b in 1H 2025, with basic EPS losses of C¥0.62, C¥2.11 and C¥0.18 respectively. Investors are likely to focus on how these headline numbers compare with expectations around...

Jinshang Bank (SEHK:2558) has put fresh numbers on the table for FY 2025, with first half revenue of C¥1.96b and basic EPS of C¥0.18 setting the tone for how the rest of the year may be judged. Over recent periods the bank has seen revenue move between C¥1.96b and C¥2.16b per half year, while basic EPS has ranged from C¥0.12 to C¥0.18. This gives you a clear view of how the income line and per share earnings have been tracking into this latest report. With a net profit margin in the low 40s...

China Risun Group (SEHK:1907) has reported FY 2025 first half revenue of C¥20.5b and basic EPS of C¥0.0066, with the latest twelve month figures showing revenue of C¥39.3b and basic EPS of C¥0.013. The company has seen revenue move from C¥25.2b in the first half of 2024 to C¥22.3b in the second half of 2024 and then to C¥20.5b in the first half of 2025. Over the same periods, basic EPS shifted from C¥0.025383 to a loss of C¥0.021219 and then to C¥0.0066, setting up an earnings story that now...

Event context and recent share performance Ascentage Pharma Group International (SEHK:6855) has attracted investor attention recently, with the share price moving 7.5% over the past week and 7.5% over the past month, against a small decline in the past 3 months. Over a longer horizon, the stock shows a negative year to date return, alongside a 6.9% 1 year total return. This gives investors a mixed backdrop to assess the company’s clinical stage biotech profile and current valuation...

Innovent Biologics (SEHK:1801) has drawn investor attention after recent share price moves, with the stock up 7.7% over the past day and 5.5% over the past week, inviting a closer look at its current valuation. See our latest analysis for Innovent Biologics. That 7.7% 1 day share price return and 8.5% year to date share price return sit against a 1 year total shareholder return of 85.1% and a 3 year total shareholder return of 143.2%, suggesting momentum has been building over time as the...

AIA Group (SEHK:1299) has drawn investor attention after recent share price moves, with the stock showing mixed returns over the past month and past 3 months, alongside reported revenue of $26,215m and net income of $6,234m. See our latest analysis for AIA Group. Over the past year, AIA Group’s share price return has been more muted than its 47.66% total shareholder return. This suggests dividends and other distributions have played a meaningful role even as recent short-term share price...

AsiaInfo Technologies Limited's ( HKG:1675 ) earnings announcement last week didn't impress shareholders. Despite the...

As you might know, Jiumaojiu International Holdings Limited ( HKG:9922 ) last week released its latest annual, and...

NagaCorp Ltd. recently reported full-year 2025 results, with revenue of US$709.67 million and net income of US$309.91 million, and proposed a final dividend of US$0.0109 per share subject to shareholder approval on 25 June 2026. The combination of higher earnings per share of US$0.0701 and a new final dividend proposal signals management’s confidence in the company’s financial position. With these results and the proposed final dividend under consideration, we’ll explore how this payout...

China Conch Venture Holdings (SEHK:586) has come into focus after releasing its full year 2025 results, reporting sales of CN¥6,547.71 million and net income of CN¥2,245.14 million, alongside higher basic earnings per share. See our latest analysis for China Conch Venture Holdings. The latest full year earnings release has arrived alongside a shifting share price picture, with the stock at HK$11.95 after a 1 day share price return of 2.14% and a 7 day share price return of 8.64%. While the 90...

Why Simcere’s latest earnings and cancer trial update matter for investors Simcere Pharmaceutical Group (SEHK:2096) has just paired strong full year 2025 earnings with encouraging Phase I/II data for its bladder cancer therapy SIM0237, a combination that is drawing fresh attention from investors. See our latest analysis for Simcere Pharmaceutical Group. The latest 7.96% 1 day share price return to HK$12.07, alongside a 52.80% 1 year total shareholder return and solid multi year gains, points...

China Resources Gas Group (SEHK:1193) released its full year 2025 results, reporting sales of HK$97,732.61 million and net income of HK$3,546.79 million, both lower than the previous year, which helps frame the current focus of investors. See our latest analysis for China Resources Gas Group. The recent full year results, which showed lower sales and net income, appear to sit alongside weaker momentum in the share price. The 90 day share price return shows a decline of 16%, and the 1 year...

Amidst the backdrop of geopolitical tensions in the Middle East and fluctuating energy prices, Asian markets are navigating a complex landscape that influences investor sentiment across various sectors. As investors seek opportunities within this environment, penny stocks—though often considered niche—continue to attract attention for their potential to offer growth at a lower entry cost. These stocks, typically representing smaller or newer companies, can present significant value when...

As geopolitical tensions in the Middle East and volatile energy prices continue to influence global markets, Asian equities have been impacted by these developments, with investors closely watching how economies in the region navigate rising inflationary pressures. In this context, dividend stocks can offer a measure of stability and income potential, making them an attractive option for those looking to weather uncertain times while benefiting from consistent payouts.

Debt repurchase prompts fresh look at China Water Affairs Group China Water Affairs Group (SEHK:855) has repurchased and cancelled US$25,000,000 of its outstanding notes, about 7.1% of the original issue. This trims the remaining balance to US$325,000,000. See our latest analysis for China Water Affairs Group. The HK$4.94 share price has recently seen a 1.65% 1 day gain, but this follows a 6.44% year to date share price decline and a 22.04% 1 year total shareholder return decline, suggesting...

Why SY Holdings Group (SEHK:6069) is Back on Investors’ Radar SY Holdings Group (SEHK:6069) has drawn fresh attention after its 2025 earnings showed higher net income alongside slightly lower revenue, paired with a special dividend and a recommended increase in the final cash dividend. See our latest analysis for SY Holdings Group. Despite the latest earnings and dividend announcements, the 7 day share price return of a 10.0% decline and the 30 day share price return of a 13.48% decline at...

Why Country Garden Services Holdings is back in focus Country Garden Services Holdings (SEHK:6098) has drawn fresh attention after reporting full year 2025 results, which showed higher sales but a sharp drop in net income, alongside the completion of a sizeable share buyback program. See our latest analysis for Country Garden Services Holdings. The share price reaction has been mixed, with a 3.32% 1 day share price return and a 1.54% 7 day share price return, set against a 6.33% 30 day share...

United Company RUSAL International (SEHK:486) has released its full year 2025 results, reporting sales of US$14.8b and a net loss of US$455 million, a clear change from the prior year’s profit. See our latest analysis for United Company RUSAL International. The earnings release and upcoming board meeting on March 20 come against a weak backdrop, with a 30 day share price return of a 23.08% decline and a year to date share price return of a 15.11% decline, while the 3 year total shareholder...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Everest Medicines Limited recently reported full-year 2025 results, with sales of CNY 1,706.68 million versus CNY 706.68 million a year earlier and a net loss of CNY 297.77 million compared with CNY 1,041.38 million, alongside presentations at the American College of Cardiology 75th Annual Scientific Session in New Orleans in March 2026. The sharp increase in revenue and much smaller loss per share point to materially improved operating efficiency that could reshape how investors view the...